Sinocare Inc (300298) - Total Liabilities
Based on the latest financial reports, Sinocare Inc (300298) has total liabilities worth CN¥2.57 Billion CNY (≈ $376.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 300298 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Sinocare Inc - Total Liabilities Trend (2008–2024)
This chart illustrates how Sinocare Inc's total liabilities have evolved over time, based on quarterly financial data. See 300298 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Sinocare Inc Competitors by Total Liabilities
The table below lists competitors of Sinocare Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
USA | $28.01 Million |
|
IMDEX Ltd
AU:IMD
|
Australia | AU$200.79 Million |
|
CTS Corporation
NYSE:CTS
|
USA | $242.72 Million |
|
ShanXi Coking Co Ltd
SHG:600740
|
China | CN¥10.72 Billion |
|
Zhongsheng Group Holdings Limited
F:5Z0
|
Germany | €60.19 Billion |
|
Accelerant Holdings
NYSE:ARX
|
USA | $7.88 Billion |
|
VA Tech Wabag Limited
NSE:WABAG
|
India | Rs31.33 Billion |
|
SFL Corporation Ltd
F:UG6
|
Germany | €2.68 Billion |
Liability Composition Analysis (2008–2024)
This chart breaks down Sinocare Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300298 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinocare Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinocare Inc (2008–2024)
The table below shows the annual total liabilities of Sinocare Inc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.33 Billion ≈ $340.65 Million |
-5.22% |
| 2023-12-31 | CN¥2.46 Billion ≈ $359.43 Million |
+66.68% |
| 2022-12-31 | CN¥1.47 Billion ≈ $215.63 Million |
+8.26% |
| 2021-12-31 | CN¥1.36 Billion ≈ $199.18 Million |
+17.86% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.99 Million |
+82.57% |
| 2019-12-31 | CN¥632.57 Million ≈ $92.56 Million |
+67.78% |
| 2018-12-31 | CN¥377.01 Million ≈ $55.17 Million |
+38.01% |
| 2017-12-31 | CN¥273.18 Million ≈ $39.98 Million |
+39.61% |
| 2016-12-31 | CN¥195.68 Million ≈ $28.63 Million |
+108.41% |
| 2015-12-31 | CN¥93.89 Million ≈ $13.74 Million |
-6.58% |
| 2014-12-31 | CN¥100.51 Million ≈ $14.71 Million |
-2.14% |
| 2013-12-31 | CN¥102.71 Million ≈ $15.03 Million |
+1.59% |
| 2012-12-31 | CN¥101.10 Million ≈ $14.79 Million |
+63.93% |
| 2011-12-31 | CN¥61.67 Million ≈ $9.02 Million |
+11.95% |
| 2010-12-31 | CN¥55.09 Million ≈ $8.06 Million |
+85.06% |
| 2009-12-31 | CN¥29.77 Million ≈ $4.36 Million |
+149.68% |
| 2008-12-31 | CN¥11.92 Million ≈ $1.74 Million |
-- |
About Sinocare Inc
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People's Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic disease… Read more